Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Metagenomix
AddedMar 20, 2024
UpdatedJun 18, 2026
Metagenomix

Metagenomix

Seed

Developing software to screen microbes for pharmacologically active compounds and identify bacterial metabolites.

HQ
Branford, CT, US
Founded
2010
Overview
Compare
Fundraising
Employees

Metagenomix Inc develops methods of screening microbes for pharmacologically active compounds.

The Company also devises high throughput methods of identifying bacterial metabolites with pharmacological activity in organisms which currently cannot be grown using standard laboratory techniques.

Metagenomix - Similar Companies

Biomiic logo

Biomiic

Biosortia Microbiomics logo

Biosortia Microbiomics

biosortia.com

Aperiomics logo

Aperiomics

Phylagen logo

Phylagen

Pathogenetix logo

Pathogenetix

Bacterial Barcodes logo

Bacterial Barcodes

Flexomics logo

Flexomics

flexomics.com

PhagePro logo

PhagePro

phageproinc.com

PanGenX logo

PanGenX

Microbiome Therapeutics logo

Microbiome Therapeutics

MicrobeDx logo

MicrobeDx

microbedx.com

CapForce logo

CapForce

opgen.com

Microbial Pulse Diagnostics logo

Microbial Pulse Diagnostics

Attometrics logo

Attometrics

Microbiotix logo

Microbiotix

microbiotix.com

Metagenomix - Quick Facts

Who are Metagenomix's competitors?

Companies similar to Metagenomix include Biomiic, Biosortia Microbiomics, Aperiomics and Phylagen.

When was Metagenomix founded?

Metagenomix was founded in 2010.

Where is Metagenomix's headquarters located?

Metagenomix's headquarters is located in Branford, CT, US.

When was Metagenomix's last funding round?

Metagenomix's most recent funding round was for $700k (USD) in April 2010.

How much has Metagenomix raised to-date?

As of Apr 13, 2010, Metagenomix has raised a total of $700k (USD).

How many employees does Metagenomix have?

Metagenomix has 6 employees as of Feb 5, 2024.

Metagenomix - Classification

Ownership
  • Private
  • Venture Capital
Technology
  • Analytics
Geographic Exposure
  • Global
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Pharmacology Software
Tags
  • Biotech
  • SaaS
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 325000Chemical Manufacturing
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2800Chemicals And Allied Products
  • 2830Drugs
  • 2834Pharmaceutical Preparations